Market Overview

UPDATE: Morgan Stanley Downgrades Mylan to Equal-Weight Following Outperformance

Share:
Related MYL
Wall Street's M&A Chatter From January 19
The Difference Between Mylan's EpiPen And Generic Offerings
Teva's Got Potential - And The Complexity To Go With It (Seeking Alpha)

Morgan Stanley downgraded Mylan Inc. (NASDAQ: MYL) from Overweight to Equal-weight and removed the price target of $27.00.

Morgan Stanley commented, "Mylan is above our previous $27 price target, and we are downgrading from OW to EW on a more balanced risk-reward. The market now appears to be pricing in better growth prospects in EMEA and the potential for accretive M&A."

Mylan closed at $27.91 on Monday.

Latest Ratings for MYL

DateFirmActionFromTo
Jan 2017CitigroupDowngradesBuyNeutral
Oct 2016MizuhoInitiates Coverage OnBuy
Oct 2016Raymond JamesUpgradesMarket PerformStrong Buy

View More Analyst Ratings for MYL
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (MYL)

View Comments and Join the Discussion!